Form 4: Provectus CEO Acquires $45K Convertible Note in 2025 Financing

Provectus Biopharmaceuticals CEO Edward Pershing acquired an 8% unsecured convertible promissory note valued at $45,000, convertible into Series D-1 Preferred Stock.

Summary

• Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), acquired an 8% unsecured convertible promissory note with a principal value of $45,000.
• The note was issued on December 11, 2025, as part of the Issuer's 2025 Financing.
• The note is convertible into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• Conversion can be voluntarily elected by the reporting person at any time while the note is outstanding.
• The note will automatically convert into Series D-1 Preferred Stock on December 11, 2026, which is twelve months after its issue date.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• Series D-1 Preferred Stock will automatically convert into Common Stock on June 26, 2026, unless converted earlier.

Sentiment

Score: 6

Explanation: Slightly positive. Insider participation in financing generally signals confidence, but the use of convertible debt introduces future dilution risk, balancing the sentiment.

Positives

• The acquisition of the convertible note by CEO Edward Pershing demonstrates insider confidence in the company's future.
• The transaction is part of the company's 2025 Financing, indicating successful capital raising efforts to support operations or development.

Negatives

• The issuance of convertible debt, while providing financing, introduces potential future dilution for existing common shareholders upon conversion of the note and preferred stock.

Risks

• Potential dilution of common stock value if the convertible note and subsequent preferred stock are converted into common shares.
• The complex conversion structure involving both a promissory note and preferred stock could lead to uncertainty regarding future share count.

Future Outlook

The convertible note is part of the Issuer's 2025 Financing, suggesting ongoing capital deployment for company operations or strategic initiatives. The conversion terms outline future potential increases in the company's outstanding share count.

Industry Context

Convertible notes and preferred stock issuances are common financing mechanisms for biotechnology companies, particularly those in development stages, to raise capital while managing immediate equity dilution and offering investors potential upside.

Related Party Transactions

• Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc., acquired an 8% unsecured convertible promissory note from the company, constituting a related party transaction.

Stakeholder Impact

• Shareholders: Potential future dilution of common stock value due to the conversion of the note into preferred stock and then into common stock.

Next Steps

• Potential voluntary conversion of the 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.
• Automatic conversion of the note into Series D-1 Convertible Preferred Stock on December 11, 2026.
• Automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock on June 26, 2026, or earlier voluntary conversion.

Key Dates

Keywords

Provectus Biopharmaceuticals, PVCT, Form 4, Insider Transaction, Convertible Note, Series D-1 Preferred Stock, Financing, Edward Pershing, Biotechnology